Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wurzburg biotech flourishing:

This article was originally published in Clinica

Executive Summary

The German city of Wurzburg is making a name for itself as a centre for biomedicine. Two companies from the area, OncoMab and Osteogenetics, took first and second prize in the recently held Businessplan-Competition (Businessplan-Wettbewerb) for North Bavaria, which aims to initiate the foundation of innovative companies and lend support during their preliminary growth phase. OncoMab is a spin-off from the pathology institute of the University of Wurzburg and is involved in the development of human monoclonal antibodies for use in cancer therapy. The advantage of human anti-bodies, says the company, is that, while they are the "most effective" method of combating chronic disease, they are extremely well tolerated by the patient. Osteogenetics, founded by two oral surgeons from Wurzburg, develops biomaterials used in the healing of bone defects. The company intends to focus on the employment of bone growth factors in the regeneration of cartilage. The Businessplan-Wettbewerb was originally established in various regions of Germany by McKinsey & Co to support innovative, mainly scientific start-up companies. The competitions now have a wider group of sponsors.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072108

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel